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MEETING PROCEEDINGSThe 2008 Annual Scientific Session of the American Heart
Association was held in New Orleans from November 9 to
12, 2008. Many innovative clinical and scientific develop-
ments were presented and discussed at the meeting. The
American Heart Association meeting is unique in that all
major specialties treating cardiovascular disease are repre-
sented, including cardiac surgery, cardiology, neurology,
basic science, and imaging.
This year, cardiac surgery was especially well repre-
sented. Dr Tim Gardner presented his Presidential address,
Dr Philippe Menasche´ gave the Paul Dudley White Interna-
tional Lecture, and Dr Tirone David presented the William
W. L. Glenn Lecture entitled ‘‘Aortic Valve Sparing:Match-
ing the Procedure to the Aortic Root Pathology.’’ In his Pres-
idential address, Dr Gardner challenged the audience to
become citizen leaders with a ‘‘passion for prevention’’ to
reduce heart disease and stroke. Worldwide heart disease
mortality rates peaked approximately 30 years ago and
have been declining, largely because of preventative mea-
sures. Dr Gardner noted ‘‘Despite this progress, serious
challenges remain. The major threat to continued reductions
in preventable and premature deaths from cardiovascular
disease and stroke is the increase in the risk factors of obesity
and diabetes, untreated high blood pressure, smoking and
lack of physical activity,’’ especially in developing coun-
tries. Gardner called on all health care professionals to con-
tinue their work to build a healthier world by raising money
to support research and providing resources to drive preven-
tion and health promotion efforts. He concluded by promot-
ing preventative medicine and healthy lifestyles, not only in
North America and Europe but also throughout the world.
Dr Philippe Menasche´ gave the Paul Dudley White Lec-
ture, entitled ‘‘Human Cardiac Cell Therapy—Lessons
Learned and Future Prospects.’’ Dr Menasche reviewed
studies of stem cell therapies, including intracoronary infu-
sion of bone marrow-derived mononuclear cell and mesen-
chymal stem cells for the treatment of acute myocardial
infarction (MI) and the delivery of embryonic stem cells
for the treatment of chronic heart failure. Although Dr
Menasche did outline the progress that has been made, he
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hoped. With current techniques, most cells die or do not
functionally engraft into the host organ. The lessons learned
include the choice of cells, a better understanding of graft–
host interactions, the development of methods to improve
cellular survival, and the incorporation of the transplanted
cells into the host so that they survive and incorporate into
the host organ with real clinical improvement.
BASIC/TRANSLATIONAL RESEARCH
It was shown in a fibrillin-deficient mouse model of
Marfan syndrome that pravastatin at 50 mg/kg/d attenuated
aortic root dilatation and thickening of the aortic media over
an observation period of 6 months.1 Although exact mecha-
nisms are unclear, other results obtained with this mouse
model indicated that the combination of oral doxycycline
and oral losartan also could prevent dilatation of the ascend-
ing aorta, with concomitant decreases in the activities of
matrix metalloproteinase-2 and -9, as well as a reduction in
transforming growth factor-b expression.2 Taken together,
these observations provide some hope for the possibility of
future primary and secondary prevention in patents with
Marfan syndrome.
In the field of cell therapy, Gorman and colleagues3
reported that allogenic mesenchymal progenitor cells
(MPCs) injected intramyocardially 1 hour after acute MI
in sheep could not be found 8 weeks later. Although this
has been observed by other groups, they also found that
this was independent of the number of cells delivered (up
to 450 3 106 cells) and that, despite the absence of cells,
the functional effect on the prevention of left ventricular di-
latation correlated with higher injected MPC numbers and
a proportional decrease in collagen turnover.
Huang and colleagues4 showed that the so-called immune
privilege of MPCs is not sustained, and that it is lost 1 to 5
weeks post-injection, possibly coincident with myogenic
differentiation of the MPCs, but without any significant im-
pact on functional effects such as left ventricular ejection
fraction.4 Clearly, the field has much work to do to resolve
such issues of ‘‘mechanistic-functional dissociation.’’
ACUTE CORONARY SYNDROME
Rosuvastatin in Patients with Elevated C-Reactive
Protein
The JUPITER trial, a randomized, double-blind, placebo-
controlled, multicenter trial testing whether a lipid-lowering
drug reduces heart attacks in people with normal cholesterol
but high levels of high-sensitivity C-reactive protein (hs-
CRP), attracted much interest at the meeting. Hs-CRP is
a marker of inflammation that can be associated with in-
creased coronary disease risk. Among 17,802 patients withardiovascular Surgery c Volume 137, Number 3 791
Meeting Proceedings Kang et alelevated hs-CRP, patients receiving 20 mg rosuvastatin had
a 44% reduction in first major cardiovascular events. There
was a 37% reduction in first cardiac events in the statin
group who had no risk factors except elevated hs-CRP, sug-
gesting a potential role of rosuvastatin in patients with
elevated hs-CRP with normal cholesterol. This study was
recently published in the New England Journal of Medicine
in November 2008.5
New Anticoagulation Strategies
Anticoagulation during acute coronary syndrome intro-
duces dilemmas to surgeons because these patients often
require coronary artery bypass grafting (CABG) after car-
diac catheterization. Two interesting studies on new antico-
agulation strategies were presented at the late-breaking trial
sessions. The first addressed the widely used clopidogrel. In
429 patients undergoing percutaneous coronary intervention
(PCI) who had a low response to an initial 600 mg clopidog-
rel loading dose, as defined by a vasodilator-stimulated
phosphoprotein (VASP) index of less than 50%, the patients
were randomized to receive either the usual single 600-mg
dose of clopidogrel or up to 3 additional 600-mg clopidogrel
doses (up to 2400 mg) to obtain a predefined, adequate anti-
platelet response (VASP index>50%).6 The VASP index
has been shown to be a highly specific measure of a patient’s
antiplatelet response to clopidogrel.7 Researchers reported
that individually tailoring the loading dose of clopidogrel
was associated with a significant 88% reduction in the rate
of early stent thrombosis and 94% reduction in the rate of
major adverse cardiovascular events compared with the
standard clopidogrel dose.
In another study, 3491 patients who were already taking
either aspirin alone or aspirin plus thienopyradine were
randomized to also receive either placebo or rivaroxaban,
a new oral, direct factor Xa inhibitor. Although there was
a dose-dependent increase in mild bleeding with rivaroxaban
compared with the placebo (2–4.5-fold increase with higher
doses), there was also a 20% trend toward a benefit in the
rate of death, MI, stroke, or need for revascularization.8
This study thus suggests that additional benefit might be
achieved in patients with acute coronary syndrome who
are already receiving the usual anticoagulation regimen by
the addition of rivaroxaban. On the basis of the safety and
efficacy outcomes, a study of different dosing regimens of
rivaroxaban is planned in a phase III trial.
Also, in a late breaking clinical trial presentation, the
safety and possible benefits of rFVIIa in patients undergoing
cardiac surgery were assessed. A total of 172 patients who
had undergone cardiac surgery and were bleeding were ran-
domized to receive placebo, 40 mg/kg rFVIIa, or 80 mg/kg
rFVIIa. The authors reported more serious adverse events in
the rFVIIa groups, but the differences did not reach statisti-
cal significance (placebo: 7%; 40 mg/kg: 14%; P ¼ .25; 80
mg/kg: 12%; P¼ .43). After the trial drug administration, in792 The Journal of Thoracic and Cardiovascular Surcomparison with the placebo, significantly fewer patients in
the rFVIIa group underwent reoperation because of bleeding
(P ¼ .03) or required transfusions (P¼ .03). On the basis of
this preliminary evidence, rFVIIa was believed to be benefi-
cial to treat bleeding after cardiac surgery, but caution
should be applied and further clinical trials are required.
INTERVENTIONAL CARDIOLOGY
Bare Metal Stent versus Drug-eluting Stent
Although drug-eluting stents (DES) have been shown to
reduce the rate of repeat revascularization compared with
bare metal stents (BMS), there have been recent controver-
sies over their potential long-term safety. Several studies
addressed long-term safety issues, particularly 2 abstracts
by Dr Patrick Serruys’ group from The Netherlands. In the
first study, the 5-year clinical event rates evaluation of 958
patients treated with sirolimus-eluting stents (SES) from
the RESEARCH registry (508 patients treated with SES
and 450 patients treated with BMS) showed that the 5-
year, all-cause mortality rates were comparable (14.0% for
SES vs 13.4% for BMS, P ¼ .9).9 In the second study,
the investigators compared 576 patients treated with pacli-
taxel-eluting stents from the T-SEARCH registry compared
with 508 patients treated with SES from the RESEARCH
registry.10 The 4-year cumulative major adverse event rates
were equivalent (30.5% SES vs 30.7% paclitaxel-eluting
stents, P ¼ .9). Further supporting this conclusion, a meta-
analysis of more than 192,000 patients enrolled in 22 ran-
domized, controlled trials and in 34 observational studies
demonstrated that DES was not associated with a greater
percentage of adverse safety outcomes, such as death or
MI, but did achieve a significant reduction in target vessel
revascularization compared with BMS.11 Further indicating
the benefit of DES compared with BMS, studies of diabetic
patients from theMass-DAC registry and patients with prox-
imal coronary lesions from the National Heart, Lung, and
Blood Institute Dynamic Registry also suggest that DES re-
sults in significant decreases in death or MI, as well as the
need for repeat revascularization compared with BMS.12,13
Primary Percutaneous Transluminal Coronary
Angioplasty versus Primary Stenting in Patients with
Early Coronary Artery Bypass Grafting
Whether balloon angioplasty without stent placement
(primary percutaneous transluminal coronary angioplasty
[PTCA]) is adequate or stent implantation is necessary in pa-
tients presenting with ST-elevation MI for whom early
CABG is planned is not known. Investigators from Duke
University examined 2982 patients with ST-elevation MI
treated with primary PTCA (n ¼ 1494) or primary stenting
(n ¼ 1488) to evaluate if the strategy of primary PTCA ver-
sus primary stenting had any differences in clinical events in
the first 30 days.14 Compared with primary stenting, primary
PTCA was associated with higher rates of target vesselgery c March 2009
Kang et al Meeting Proceedingsrevascularization at 30 days, but with no increase in death or
reinfarction. This study thus suggests that primary PTCA
may be a reasonable option in patients who are planned
for early CABG, allowing a shorter course of potent antipla-
telet therapy and permitting earlier CABG compared with
those patients receiving stents.
Stenting versus Coronary Artery Bypass Grafting
Malenka and colleagues,15 for the Northern New England
Cardiovascular Disease Study Group, reported on registry
patients who received either PCI with DES (DES-PCI)
(N¼ 2520) or CABG (N¼ 2626) for non-emergency multi-
vessel disease. Although there was a small but statistically
significant increase in 45-day mortality (0.4% for DES-
PCI vs 1.8% for CABG) in favor of the DES-PCI group,
these differences vanished by approximately 15 months
postprocedure and actually translated into significantly
higher overall mortality rate in DES-PCI (4.1%/year) com-
pared with patients who underwent CABG (2.2%/year).
Similar findings were also observed in a large single-center
study from Beijing, China, where 2-year rates of target ves-
sel revascularization (13% for DES-PCI vs 1.4% for
CABG), MI rates (hazard ratio 1.6 for DES-PCI vs
CABG), and total mortality (hazard ratio 1.6 for DES-PCI
vs CABG) were significantly higher with DES-PCI than
with CABG.16 Furthermore, CABGwas associated with sig-
nificantly lower costs by 1 year post-procedure. Notably,
a unique feature of these studies from New England and
China is that all patients in the PCI group received DES.
McGinn and colleagues17 presented a series of 300 con-
secutive patients who underwent multivessel minimally in-
vasive CABG via a small thoracotomy, under direct vision
and without the need for endoscopic or robotic assistance.
The procedure was reported to be safe (0.7%), with low
atrial fibrillation, stroke, and wound infection rates. It al-
lowed for all coronary distributions to be grafted (with up
to 4 grafts per patient in the series), as well as performance
of total arterial grafting and hand-sewn proximal anastomo-
ses onto the aorta, as per a standard CABG operation.
Endovascular Stent-Graft Repair of Type B Aortic
Dissection
The potential effectiveness of endovascular stent-graft re-
pair of type B aortic dissection was demonstrated by inves-
tigators from South Korea in a retrospective analysis of 73
patients who underwent stent-graft repair from 1994 to
2007.18 The indications for case selection were progression
of dissection despite adequate medical treatment, dynamic
obstruction, intractable pain, aortic diameter of 6 cm or
more, or continuous false lumen leakage. The analysis
showed the achievement of 92% angiographic success
(immediate closure of the entry site without any significant
endoleak) and 73% clinical success (complete obliteration
of the false lumen). The complication rate was 30% (eg, per-The Journal of Thoracic and Csistent endoleak, false lumen flow patency) and the mortality
rate was 5.5% at 43 months follow-up. On the basis of these
favorable clinical outcomes, stent-graft repair may be con-
sidered a safe and effective treatment option of type B aortic
dissection, particularly in patients with a high risk for surgi-
cal morbidity or mortality.
VALVULAR DISEASE
Percutaneous Aortic Valve Replacement
Although percutaneous aortic valve replacement (PAVR)
is increasingly being used to treat patients with aortic stenosis
who are poor candidates for surgery, the clinical outcomes of
these patients are still not fully evaluated. A study from The
Netherlands followed 81 patients for 1 year who were treated
between 2005 to 2008 with the CoreValve (CoreValve Inc,
Irvine, Calif), a self-expanding pericardial valve system.19
PAVR was complicated by a stroke in 4 patients (5%) and
MI in 2 patients (2%). In these very high risk and mostly
elderly patients, the 30-day and 1-year mortality rates were
4% and 15%, respectively, and there was no evidence of sig-
nificant valvular dysfunction. Thus, these findings suggest
that PAVR may be a safe and effective option for high-
risk, elderly patients with severe aortic stenosis.
Aortic Valve Replacement in the Elderly
In a study from the Northern New England Cardiovascu-
lar Study Group, Likosky and coauthors20 found in approx-
imately 4000 patients that survivorship in very elderly
patients (85 years) after surgical AVR was 89.7% for
AVR alone and 90.1% for AVR-CABG, and that in both
groups the median survival was reasonable at approximately
6 years. However, it remains likely that very elderly patients
who undergo surgical AVR are selected, as was reported in
a smaller study indicating that 49% of patients with severe
aortic stenosis (mean gradient  40 mm Hg) who presented
to 3 tertiary centers did not undergo AVR, for a number of
reasons that included age and comorbidities.21
ARRHYTHMIA
Ablation in Mitral Valve Surgery for Atrial
Fibrillation
In the MAMA trial, 64 patients with permanent atrial fi-
brillation were randomly assigned to mitral valve surgery
plus left and right atrial microwave ablation (31 patients)
or mitral valve surgery alone (33 patients).22 At 12 months,
sinus rhythm was restored in 81% of the ablation group ver-
sus 36% of the control group. Thus, this study suggests that
microwave ablation in the left and right atria in conjunction
with mitral valve surgery is a safe and effective method to
restore sinus rhythm in patients with long-lasting, permanent
atrial fibrillation compared with mitral valve surgery alone.
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